Top Stories
Arcera gains exclusive rights across emerging markets, including Latin America and the Middle East.
The agreement will see the companies combine their resources to hunt for small-molecule drug candidates targeting oncology.
In conjunction with the move, nChroma Bio will undertake a restructuring, which news sources suggested will cut the biotech's workforce by around half.
Chief medical officer Eric Hughes will step down, to be replaced on an interim basis by David Gardiner, who heads innovative medicines and clinical development, until a permanent successor is found.
The agency will make a decision on sonesitatug vedotin in the second quarter of 2027.
Conference News
Summit’s FDA climb just got steeper with ivonescimab snubWhile the FDA's rejection of Summit Therapeutics and Akeso's ivonescimab didn't come as a complete surprise for those paying attention, the com...
Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, h...
November 19, 2026 Alyssum Therapeutics Inc., a clinical stage biopharmaceutical company developing a pipeline of first in class therapeutics through a patented technology platform, today announced a l...
Four studies examine how asthma education, access to advanced treatments and the risks of long-term steroid use can affect patient care, while highlighting gaps in recognizing uncontrolled asthma.FAIR...
Phase 1 data presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, showed deep and durable responses in...




